Potential Cancer Drug as Autism Treatment
At a press conference on various autism-related topics, U.S. health officials hinted that certain cancer medications might also serve as treatments for neurodevelopmental disorders. FDA Commissioner Marty McCurry, NIH Director Jay Bhattacharya, and Medicare and Medicaid Administrator Mehmet Oz shared findings indicating that leucovorin, a prescription vitamin prescribed for cancer and anemia, could be beneficial for children with autism.
The Department of Health and Human Services announced plans for the FDA to approve leucovorin as a potential treatment addressing language deficits linked to autism spectrum disorder (ASD). This approval would also update the drug’s label to reflect its use in addressing brain folate deficiencies associated with autism.
After this label modification, Medicaid programs across various states are expected to cover treatments utilizing this drug for autism. The NIH is also set to begin a research initiative focusing on the safety and effectiveness of leucovorin.
Understanding Leucovorin
Research indicates that leucovorin may aid some nonverbal children in developing speech. Katy Dubinsky, a New York pharmacist and co-founder of a supplement company, noted that leucovorin acts similarly to folic acid, aiding those who have difficulty absorbing or utilizing it.
While leucovorin is primarily FDA-approved for reducing toxic side effects from certain cancer treatments, some families report that its off-label use has led to noticeable improvements in communication skills for children with autism.
Dr. Richard E. Fry, a child neurologist in Arizona, conducted a study on experimental treatments for ASD and remarked on leucovorin’s unique properties. “It’s a special form of vitamin B9 that is water soluble and doesn’t accumulate in the body,” he explained.
Though not officially prescribed for autism, reports suggest that families have seen significant gains in their children’s communication abilities with its off-label application. “Leucovorin appears to help a considerable number of children with autism,” Fry noted, emphasizing that enhanced language skills were notably measured in clinical trials.
Dr. Mark Siegel from NYU Langone Health affirmed that high doses of leucovorin compared to regular vitamins necessitate working closely with knowledgeable medical professionals. He explained, “Central folate deficiency can disrupt neurological functions. Many children with autism spectrum disorders have shown antibodies that could affect brain function.”
Although leucovorin seems promising, larger studies are still needed to better understand its impact on neural functions and communication skills in children with ASD.
Expert Insights
Using leucovorin carries reduced risks due to its long-established use in other medical contexts, according to doctors. “Its history in chemotherapy protection gives us a clear picture of dosing and potential side effects,” Fry added.
Nonetheless, some children may experience hyperactivity or may not respond positively to the treatment, leading to the need for alternative therapies. Fry strongly advises families to consult with medical professionals when considering leucovorin for autism intervention.
Though available at pharmacies, some children may need a specialized form based on sensitivities to certain additives. Fry expressed a desire for leucovorin to receive FDA approval specifically for autism treatment, making it more widely accessible post-diagnosis.
Dubinsky echoed that clinical judgments and emerging evidence could guide doctors in prescribing this well-tolerated drug, although the importance of clinical trials cannot be overlooked.
With FDA approval, the medical community could see more standardized protocols, insurance coverage, and greater acceptance for leucovorin’s use in treating autism. However, Fry cautioned that autism treatments often require a combination approach, stating, “It’s improbable that leucovorin will serve as a standalone solution; integrating it with behavioral and speech therapies is likely the most effective strategy.”
Dr. Andy Shee, Chief Science Officer in New York, mentioned that each child with autism presents a unique experience. He stressed the importance of individualized treatment plans and the need for larger controlled trials to validate small observational studies.
In summary, while promising, the future of leucovorin as a treatment option for autism remains uncertain and calls for thorough exploration and validation through comparative clinical research.
